A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Learn about the financial strain caused by the skyrocketing demand and costs of GLP-1 drugs, and how health plans and providers are struggling to balance it.

Drugs like Ozempic and Wegovy were already ... But given the evidence in total, Al-Aly says, “I’m more encouraged about the future of GLP-1 and its potential promise.” The study included ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

And with a growing number of companies in the GLP-1 space, investors may be losing interest in the stock. Could Viking's ...

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

According to the journal JAMA Health Forum, prescription fills for Ozempic increased by more than 400% between January 2021 ...

However, the rising popularity of GLP-1 drugs, which are highly effective in helping people lose weight and also reduce the ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...